ADC Target Selection Summit

Memo

The inaugural ADC Target Selection Summit developed in collaboration with AstraZeneca, AbbVie, Mersana and Eisai is the industry’s definitive conference dedicated to exploring the importance of ADC target selection, discussing the validation of novel targets, understanding the patient population for a certain target and therefore developing life-changing ADCs. Join your peers within target discovery from large pharma, innovative biotech and research institutes to discuss key challenges including the target-payload pairing and ensuring that it’s right from the get-go, differentiating solid tumors and hematological cancer targets and assessing the antibody for small molecule target validation. As part of the World ADC Series this virtual meeting is the go-to for scientists involved within target selection, cancer biology and bioinformatics. Be part of this focused discussion as 20+ world class experts define the criteria of what makes a good target so that you can elevate your company’s target selection strategy to create successful ADCs and accelerate more solid tumor targeting ADCs into the clinic. Tickets https://go.evvnt.com/835378-2?pid=5569 Brochure https://go.evvnt.com/835378-3?pid=5569  Prices:Drug Developer - Conference + 2 Workshops USD 2797.00Drug Developer - Conference + 1 Workshop USD 2448.00Drug Developer - Conference Only USD 2099.00Service Provider - Conference + 2 Workshops USD 3397.00Service Provider - Conference + 1 Workshop USD 2998.00Service Provider - Conference Only USD 2599.00Academic - Conference + 2 Workshops USD 2497.00Academic - Conference + 1 Workshop USD 2198.00Academic - Conference Only USD 1899.00 Speakers: Rakesh Dixit, Chief Executive Officer & Founder, BioNavigen, Bill Mallet, Staff Scientist Target Validation, Bolt Bio, Christoffer Nielson, COO & Co-founder, Adcendo, Earl Albone, Senior Director of Biochemistry & Bioanalytical Development, Eisai, Inc, Elaine Hurt, Director, Bioscience, AstraZeneca, Greg Adams, Chief Scientific Officer, Elucida Oncology, Inc, Hans Peter Gerber, Chief Scientific Officer, 3T Bioscionces, Jack Elands, Chief Executive Officer, Emergence Therapeutics, Jagath Reddy Junutula, Founder, Aarkus Therapeutics, John Lambert, Independent Consultant, Lenka Sadilkova, Director of Pharmacology, SOTIO, Martha R. Neagu, Associate Medical Director, AbbVie, Regina Reilly, Oncology Discovery, Biologics & Research Fellow, AbbVie, Robert Lawrence, Senior Scientist, Seagen, Seema Kantak, Vice President, Exelixis, Terry Rabbits, Molecular Immunologist, ICR, Tracy Kuo, Senior Director - Biology & Translational Science, Tallac Therapeutics Time: On Monday December 06, 2021 at 11:00 am (ends Wednesday December 08, 2021 at 4:30 pm)